Our guest today is Dr. Jerry Lanchbury, PhD. He's the previous chief scientific officer at Myriad Genetics. He led teams that were responsible for major molecular diagnostic innovations across oncology, urology, rheumatology, and neuroscience. He has had an incomparable track record in driving molecular genetic discovery from ideation all the way to translation into some high value clinical diagnostics. Dr. Lanchbury shares the historical context and evidence supporting polygenic risk scores (PRS), helping us understand how PRS made its way into clinical practice to fight against various cancers. He also shares why he is excited about polygenic screening of embryos and gives advice for patients seeking genetic testing.
Our guest today is Dr. Jerry Lanchbury, PhD. He's the previous chief scientific officer at Myriad Genetics. He led teams that were responsible for major molecular diagnostic innovations across oncology, urology, rheumatology, and neuroscience. He has had an incomparable track record in driving molecular genetic discovery from ideation all the way to translation into some high value clinical diagnostics. Dr. Lanchbury shares the historical context and evidence supporting polygenic risk scores (PRS), helping us understand how PRS made its way into clinical practice to fight against various cancers. He also shares why he is excited about polygenic screening of embryos and gives advice for patients seeking genetic testing.